Clinical trial · Interventional
Hypofractionated Brain Radiationcavity
Stereotactic Radiosurgery or Hypofractionated Image-Guided Radiotherapy to the Surgical Cavity After Resection of Brain Metastases: a Multicenter, Single Arm, Open-label, Phase II Trial
NCT03561896CI-TRIAL-00078869completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases, Adult | — | UNRESOLVED | — |
| Cancer Brain | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IGRT | Radiation | — | UNRESOLVED |
| SRS | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- IGRT
- description
- Image-Guided Hypofractionated Stereotactic Radiation Therapy (IGRT) of the resection cavity
- interventionNames
- Radiation: IGRT
- type
- EXPERIMENTAL
- label
- SRS
- description
- Stereotactic Radiosurgery of the resection cavity (SRS)
- interventionNames
- Radiation: SRS
Primary outcomes (1)
- measure
- Relapse rate
- timeFrame
- 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Patient underwent surgery for single brain metastasis arising from solid neoplasia (lung, breast, melanoma, kidney, colorectal), with initial histological diagnosis, or selected cases with a resected lesion and a further non-resected lesion (from 1 to 2 lesions), treatable with SRS / IGRT of the surgical cavity * Patient ≥ 18 years * Willngness to participate in the study, written informed consent * Performance Status according to WHO 0-I * Good general conditions and organ function * Newly diagnosed chemotherapy-naïve disease or controlled systemic disease * Good bone marrow, renal and hepatic function * Stable steroid dose or reduced for at least 5 days Exclusion Criteria: * History of previous brain irradiation * Pregnancy or breastfeeding * Histological diagnosis other than lung, breast, melanoma, kidney and colorectal malignancy
References
Publications (0)
Data not yet available
No reference posted for this study.